The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

CD6  -  CD6 molecule

Homo sapiens

Synonyms: T-cell differentiation antigen CD6, T12, TP120, Tp120
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CD6


Psychiatry related information on CD6

  • At T12, after adjusting for training activity, physical activity on training days was significantly lower than on non-training days (23.7 +/- 8.4 vs. 28.2 +/- 9.3 counts x min(-1); p<0.01) [5].
  • PARTICIPANTS: Nine men with T5 to T12 paraplegia, 8 of whom had complete lesions and 1 with some sacral sparing (American Spinal Injury Association grade B) without proprioception, matched to 9 able-bodied men [6].

High impact information on CD6

  • Conduction to the parietal cortex (T12-P37 interpeak latency) worsened in both the symptomatic men and the boys with preclinical adrenomyeloneuropathy [7].
  • Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand [8].
  • Here we report that CD6 expressed by COS cells mediates adhesion to TE cells and that this interaction is specifically blocked with an anti-CD6 monoclonal antibody (mAb) or with a mAb (J4-81) that recognized a TE cell antigen [8].
  • Antibody-blocking studies have demonstrated the role of CD6 in thymocyte-thymic epithelial (TE) cell adhesion [8].
  • CD6 is a 130-kD glycoprotein expressed on the surface of thymocytes and peripheral blood T cells that is involved in TCR-mediated T cell activation [9].

Chemical compound and disease context of CD6

  • Phage T14 encodes the SpeA exotoxin and is closely related to the classic converting phage T12 [10].
  • The M phenotype increased since 2000, linked to a decrease of tetracycline resistance, and was predominantly associated with T1 in 2000-2001 and T12 in 2002 among carriage isolates, and with T8/25/Imp19 through 2000-2002 among tonsillitis/pharyngitis isolates [11].
  • Cyclic dysmenorrhea was reported by 13 women with injuries ranging from C5 to T12 [12].
  • In the diabetic and control groups, after 12 weeks of training the forearm flexor muscles, power output at the intracellular threshold of acidosis (IT) increased (p < .01) similarly: T0 versus T12: 0.90 +/- 0.09 versus 1.20 +/- 0.13 and 1.03 +/- 0.07 versus 1.22 +/- 0.10 W, respectively [13].
  • A woman undergoing palliative radiotherapy to the T12 -S2 spine with concurrent bortezomib developed unexpectedly severe, acute radiation enteritis requiring hospital admission [14].

Biological context of CD6


Anatomical context of CD6


Associations of CD6 with chemical compounds

  • CD6 is a type I membrane glycoprotein expressed on thymocytes, mature T and B1a lymphocytes, and CNS cells [20].
  • The C-terminal cytoplasmic region of CD6, as well as Src tyrosine kinases, was critical for CD6-induced ERK1/2 activation [16].
  • The cytoplasmic domain of CD6 contains two serine residues, one or both of which are substrates for phosphorylation during T cell activation [21].
  • After maturation of N-linked glycan and addition of sulfated O-linked oligosaccharide, CD6 appears on the cell surface as a molecule of 130 kDa [22].
  • CD5 and CD6 co-immunoprecipitate from Brij 96 but not Nonidet P-40 cell lysates, independently of both the co-expression of other lymphocyte surface receptors and the integrity of CD5 cytoplasmic region [23].

Physical interactions of CD6

  • In this study, we report that the amino-terminal Ig-like domain of human ALCAM specifically binds to the third membrane-proximal scavenger receptor cysteine-rich (SRCR) domain of human CD6 [17].

Regulatory relationships of CD6

  • We also show that activation via CD2 induces CD6 expression on mature human thymocytes and on a subset of immature human thymocytes that are resistant to apoptosis [24].
  • Knowledge that CD166 was expressed in normal human salivary epithelium led to these studies of CD166 and CD6 in diseased mouse salivary glands, that resemble pathology seen in the human disease, Sjögren's syndrome [25].
  • However, B-CLL cells are CD5 positive and most of them also express CD6, surface receptors that are present in just a small subset of normal B-cells [26].
  • CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76 [27].

Other interactions of CD6

  • Moreover, the CD6-ALCAM interaction has been shown to be critical for proper immunological synapse maturation and T cell proliferative responses [16].
  • Of the T-cell markers, CD5, CD6, and CD7 showed lineage promiscuity by their presence on some B-NHL [28].
  • Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor [16].
  • The present study shows that CD6 ligation with three different specific mAbs (161.8, SPV-L14.2, and MAE1-C10) induces time- and dose-dependent activation of ERK1/2 on normal and leukemic human T cells [16].
  • Accordingly, CD6-mediated activation of p38 and JNK was also observed [16].

Analytical, diagnostic and therapeutic context of CD6


  1. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Degen, W.G., van Kempen, L.C., Gijzen, E.G., van Groningen, J.J., van Kooyk, Y., Bloemers, H.P., Swart, G.W. Am. J. Pathol. (1998) [Pubmed]
  2. CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Osorio, L.M., De Santiago, A., Aguilar-Santelises, M., Mellstedt, H., Jondal, M. Blood (1997) [Pubmed]
  3. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Soiffer, R.J., Gonin, R., Murray, C., Robertson, M.J., Cochran, K., Chartier, S., Cameron, C., Daley, J., Levine, H., Nadler, L.M. Blood (1993) [Pubmed]
  4. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Soiffer, R.J., Murray, C., Gonin, R., Ritz, J. Blood (1994) [Pubmed]
  5. Effect of exercise training on physical activity and substrate utilization in the elderly. Meijer, E.P., Westerterp, K.R., Verstappen, F.T. International journal of sports medicine. (2000) [Pubmed]
  6. Postural control during stance in paraplegia: effects of medially linked versus unlinked knee-ankle-foot orthoses. Middleton, J.W., Sinclair, P.J., Smith, R.M., Davis, G.M. Archives of physical medicine and rehabilitation. (1999) [Pubmed]
  7. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.C., Rocchiccioli, F., Cartier, N., Jambaqué, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C. N. Engl. J. Med. (1993) [Pubmed]
  8. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. Bowen, M.A., Patel, D.D., Li, X., Modrell, B., Malacko, A.R., Wang, W.C., Marquardt, H., Neubauer, M., Pesando, J.M., Francke, U. J. Exp. Med. (1995) [Pubmed]
  9. Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. Patel, D.D., Wee, S.F., Whichard, L.P., Bowen, M.A., Pesando, J.M., Aruffo, A., Haynes, B.F. J. Exp. Med. (1995) [Pubmed]
  10. A globally disseminated M1 subclone of group A streptococci differs from other subclones by 70 kilobases of prophage DNA and capacity for high-frequency intracellular invasion. Cleary, P.P., LaPenta, D., Vessela, R., Lam, H., Cue, D. Infect. Immun. (1998) [Pubmed]
  11. Group A Streptococci from carriage and disease in Portugal: evolution of antimicrobial resistance and T antigenic types during 2000-2002. Pires, R., Rolo, D., Gama-Norton, L., Morais, A., Lito, L., Salgado, M.J., Johansson, C., Möllerberg, G., Henriques-Normark, B., Gonçalo-Marques, J., Santos-Sanches, I. Microb. Drug Resist. (2005) [Pubmed]
  12. A prospective study of the menstrual cycle and spinal cord injury. Reame, N.E. American journal of physical medicine & rehabilitation / Association of Academic Physiatrists. (1992) [Pubmed]
  13. Metabolic response of forearm muscle to graded exercise in type II diabetes mellitus: effect of endurance training. DeVries, D.A., Marsh, G.D., Rodger, N.W., Thompson, R.T. Canadian journal of applied physiology = Revue canadienne de physiologie appliquée. (1996) [Pubmed]
  14. Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report. Mohiuddin, M.M., Harmon, D.C., Delaney, T.F. Journal of chemotherapy (Florence, Italy) (2005) [Pubmed]
  15. The membrane-proximal scavenger receptor cysteine-rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site. Whitney, G.S., Starling, G.C., Bowen, M.A., Modrell, B., Siadak, A.W., Aruffo, A. J. Biol. Chem. (1995) [Pubmed]
  16. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. Ibáñez, A., Sarrias, M.R., Farnós, M., Gimferrer, I., Serra-Pagès, C., Vives, J., Lozano, F. J. Immunol. (2006) [Pubmed]
  17. The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry. Bowen, M.A., Bajorath, J., Siadak, A.W., Modrell, B., Malacko, A.R., Marquardt, H., Nadler, S.G., Aruffo, A. J. Biol. Chem. (1996) [Pubmed]
  18. Tyrosine phosphorylation of CD6 by stimulation of CD3: augmentation by the CD4 and CD2 coreceptors. Wee, S., Schieven, G.L., Kirihara, J.M., Tsu, T.T., Ledbetter, J.A., Aruffo, A. J. Exp. Med. (1993) [Pubmed]
  19. Evidence for the expression of a second CD6 ligand by synovial fibroblasts. Joo, Y.S., Singer, N.G., Endres, J.L., Sarkar, S., Kinne, R.W., Marks, R.M., Fox, D.A. Arthritis Rheum. (2000) [Pubmed]
  20. The lymphocyte receptor CD6 interacts with syntenin-1, a scaffolding protein containing PDZ domains. Gimferrer, I., Ibáñez, A., Farnós, M., Sarrias, M.R., Fenutría, R., Roselló, S., Zimmermann, P., David, G., Vives, J., Serra-Pagès, C., Lozano, F. J. Immunol. (2005) [Pubmed]
  21. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. Aruffo, A., Melnick, M.B., Linsley, P.S., Seed, B. J. Exp. Med. (1991) [Pubmed]
  22. Biosynthesis and post-translational modification of CD6, a T cell signal-transducing molecule. Swack, J.A., Mier, J.W., Romain, P.L., Hull, S.R., Rudd, C.E. J. Biol. Chem. (1991) [Pubmed]
  23. The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells. Gimferrer, I., Farnós, M., Calvo, M., Mittelbrunn, M., Enrich, C., Sánchez-Madrid, F., Vives, J., Lozano, F. J. Biol. Chem. (2003) [Pubmed]
  24. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Singer, N.G., Fox, D.A., Haqqi, T.M., Beretta, L., Endres, J.S., Prohaska, S., Parnes, J.R., Bromberg, J., Sramkoski, R.M. Int. Immunol. (2002) [Pubmed]
  25. CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis. Abidi, S.M., Saifullah, M.K., Zafiropulos, M.D., Kaput, C., Bowen, M.A., Cotton, C., Singer, N.G. J. Clin. Immunol. (2006) [Pubmed]
  26. Regulation of B-CLL apoptosis through membrane receptors and Bcl-2 family proteins. Osorio, L.M., Jondal, M., Aguilar-Santelises, M. Leuk. Lymphoma (1998) [Pubmed]
  27. CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. Hassan, N.J., Simmonds, S.J., Clarkson, N.G., Hanrahan, S., Puklavec, M.J., Bomb, M., Barclay, A.N., Brown, M.H. Mol. Cell. Biol. (2006) [Pubmed]
  28. Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology. Schuurman, H.J., van Baarlen, J., Huppes, W., Lam, B.W., Verdonck, L.F., van Unnik, J.A. Am. J. Pathol. (1987) [Pubmed]
  29. Structure and chromosomal location of the human CD6 gene: detection of five human CD6 isoforms. Bowen, M.A., Whitney, G.S., Neubauer, M., Starling, G.C., Palmer, D., Zhang, J., Nowak, N.J., Shows, T.B., Aruffo, A. J. Immunol. (1997) [Pubmed]
  30. Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction. Starling, G.C., Whitney, G.S., Siadak, A.W., Llewellyn, M.B., Bowen, M.A., Farr, A.G., Aruffo, A.A. Eur. J. Immunol. (1996) [Pubmed]
  31. Human CD6 possesses a large, alternatively spliced cytoplasmic domain. Robinson, W.H., Neuman de Vegvar, H.E., Prohaska, S.S., Rhee, J.W., Parnes, J.R. Eur. J. Immunol. (1995) [Pubmed]
WikiGenes - Universities